Anesthesia Feasibility Study With the CONCERT-CL® Station

NCT ID: NCT02889718

Last Updated: 2019-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-16

Study Completion Date

2016-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a feasibility study of anesthesia in closed loop with the CONCERT-CL® station, on the effect of the hypnotic agent, measured by the bispectral index of the electroencephalogram, to maintain the hypnosis level within the recommended limits for general anesthesia. The analgesic agent is administered in "Target-Controlled Infusion = TCI" and analgesia evaluated by pupillometry.

This is a prospective, open, non-controlled, non-randomized, monocentric study. The main objective is to study the potential contribution of the system in the conduct of anaesthesia, as decision support, for the administration of the hypnotic agent.

Secondary objectives will include hemodynamic stability, and the average concentrations of opioid and hypnotic anesthetic agents evaluated from the pharmacokinetic model.

The study will involve surgical patients scheduled for surgery under general anesthesia for more than 1 (one) hour.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

anaesthesia with CONCERT-CL® station

During the surgery, 3 drugs usually used for anaesthesia will be administered by the CONCERT-CL® station

Group Type EXPERIMENTAL

CONCERT-CL® station

Intervention Type DEVICE

During cancer surgery (surgery \> 1 hour), CONCERT-CL® station will be used in accordance with its CE marking to administer anesthetic agents:

* Port B = open loop: Analgesic
* Port A = closed loop: Hypnotic
* Port C = closed loop: Curare

Surgery

Intervention Type OTHER

Regardless of the type of surgery the patient receives for his cancer, this surgery must be greater than 1 hour.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CONCERT-CL® station

During cancer surgery (surgery \> 1 hour), CONCERT-CL® station will be used in accordance with its CE marking to administer anesthetic agents:

* Port B = open loop: Analgesic
* Port A = closed loop: Hypnotic
* Port C = closed loop: Curare

Intervention Type DEVICE

Surgery

Regardless of the type of surgery the patient receives for his cancer, this surgery must be greater than 1 hour.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* men and women aged 18 years old and over
* Surgery of any type programmed for longer than 1 hour
* Anesthesia combining three agents: hypnotic, morphine, curare

Exclusion Criteria

* minor patient
* pregnant and lactating women
* Known or suspected hypersensitivity to propofol,
* known or suspected hypersensitivity to remifentanil and other fentanyl derivatives,
* known or suspected hypersensitivity to rocuronium and atracurium, preventing the use of the two products.
* peanut allergy, soy, Egg
* neurological disease history with known modification of the electroencephalogram
* severe eye disease, ocular implant, standing diabetes with diabetic retinopathy
* gravis
* pacemakers patient
* surgery whose position is not suitable for a monitoring on the ulnar nave
* general anesthesia associated with regional anesthesia
* Simultaneous use of shortwave therapy or microwave
* Simultaneous use of high frequency surgical apparatus
* 15 patients under supervision or unable to consent
* patient undergoing psychiatric care
* patient in a health or social institution
* emergency
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut Cancerologie de l'Ouest

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

MAVOUNGOU Philippe, MD

Role: PRINCIPAL_INVESTIGATOR

Institut de Cancérologie de l'Ouest

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ICO

Saint-Herblain, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ICO-N-2014-07

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ketamine and Closed-Loop Anesthesia System
NCT02011347 TERMINATED PHASE3